

DAFTAR PUSTAKA

- Abdurachman SA., 2007. *Buku Ajar Ilmu Penyakit Hati : Penyakit Hati Akibat Obat*. Edisi I. Jakarta : Jayabadi.
- Abdul K Najmi, KK Pillai, SN Pal, M Akhtar, M Aqil, M Sharma. *Effect of L-ornithin L-aspartate against thioacetamide-induced hepatic damage in rats*. Indian Journal of Pharmacology. 2010. 42 : 384-387.
- Abid, S., Jafri, W., Mumtaz, K., Islam, M. and Abbas, Z. *Efficacy of L-ornithine-L-aspartate as an Adjuvant Therapy in Cirrhotic Patients with Hepatic Encephalopathy*. 2011. 21: 666–671.
- Abouzid, S. 2003. Silymarin, Natural Flavonolignans from Milk Thistle. In: *Phytochemicals - A Global Perspective of Their Role in Nutrition and Health*, pp. 255 – 272.
- Acharya, S.K., Bhatia, V., Sreenivas, V., Khanal, S. and Panda, S.K. *Efficacy of L-Ornithine L-Aspartate in Acute Liver Failure: A Double-Blind, Randomized, Placebo-Controlled Study*. Gastroenterology. 2009. 136: 2159–2168.
- Afdhal N .H, Nunes D. *Evaluation of Liver Fibrosis:A concise Review*. Amer J. Gastroentology: 2004; 99:1160-1174.
- Bai X, Zhang W, Chen W, Zong W, Guo Z, Lu X. 2011. *Anti-hepatotoxic and antioxidant effect of extracts from Piper nigrum L. root*. African Journal of Biotechnology Vol 10(2) P.267-272.
- Bataller R., Brenner DA., E Miscellaneous, *Overview of liver fibrosis*, Textbook of Gastroenterology, fifth Edition. Blackwell Publishing 2009 ; 658 – 79.
- Bertini G, Dani C, Tronchin M, Rubaltelli FF. *Is breastfeeding really favoring early neonatal jaundice?*. PEDIATRICS Vol. 107 No. 3 March .2001. AAP.
- Bemion D.Arthur M.J.P; *ekstracelluler matrix degradation and the role of stellata cells*. Semin Liv Dis 2001,21; 373 – 84.
- Blackburn ST, editor. *Bilirubin metabolism, maternal, fetal & neonatal physiology, a clinical perspective*. Edisi ke-3. Saunders. Missouri; 2007.
- Boldt, J. Use of Albumin: an Update. *British Journal of Anaesthesia*. 2010. 104(3): 276-284. <http://www.ncbi.nlm.nih.gov/pubmed/20100698>. diakses pada tanggal 1 Januari 2016.
- Cahyono B. *Manajemen Perioperatif pada PAsien dengan Penyakit Hati*. Majalah Kedokteran Indonesia Vol 57 Nomor 1. 2007. <http://indonesia.digitaljournal> diakses tanggal 1 Januari 2016.
- Chattopadhyay I, Bandyopadhyay U, Biswas K, Maity P, Banerje RK. *Indomethacin inactivates gastric peroxidase to induce reactive-oxygenmediated gastric mucosal injury and curcumin protects it by preventing peroxidase inactivation and scavenging reactive oxygen*. Free Radical Biol Med. 2006; 40: 1397-408.

- Dahlan, Sopiudin., 2011. *Statistik Untuk Kedokteran dan Kesehatan Edisi 5*. Jakarta, Salemba Medika.
- Dalimartha, Setiawan. 2000. *Atlas Tumbuhan Obat Indonesia*. Jakarta : Trubus Agriwidya.
- Dewi, I.D.A.D.Y; Astuti, K.W.; Warditiani, N.K. 2013. *Skrining fitokimia ekstrak etanol 95% kulit buah manggis (Garcinia mangostana L.)*. Universitas Udayana. Jurusan Farmasi FMIPA.
- Devaraj, S., Ismail1, S., Ramanathan, S., Marimuthu, S. and Fei, Y.M. *Evaluation of the hepatoprotective activity of standardized ethanolic extract of Curcuma xanthorrhiza Roxb.* Journal of Medicinal Plants Research .2010.4: 2512–2517.
- Doumas BT, Watson W.A., Biggs H.G., *Albumin Standards and the Measurement of Serum Albumin with Bromcresol Green*. Clin Chim Acta .1971; 31:87-96.
- Dubois, M.J., dan Vincent, J.L. . *Use Of Albumin In The Intensive Care Unit*. TATM. 2002. 4: 80-4.
- El-tawil, O. S., & Moussa, S. Z. 2006. *Antioxidant and hepatoprotective effects of thymoquinone against carbon tetrachloride-induced hepatotoxicity in isolated rat hepatocytes*. Journal of the Egyptian Society of Toxicology, 34(9), 33–41.
- Evans, T.W. *Albumin As A Drug-Biological Effects Of Albumin Unrelated To Oncotic Pressure*. Review Article. Aliment Pharmacol Ther. 2002. 5: 6-11.
- Farghaly, H. S., & Hussein, M. 2010. *Protective effect of curcumin against paracetamol-induced liver damage*. Australian Journal of Basic and Applied Sciences, 4(9), 4266–4274.
- Federer, W.T. 1955. *Experimental Design. Teory and Application*. Oxford & IBH Publishing Co. New Delhi, Bombay, Calcuta.
- Feher, J. and Lengyel, G. *Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer*. Current Pharmaceutical Biotechnology. 2012. 13: 210–217.
- Feverly, J. *Bilirubin in clinical practice: a review*. Liver International, 2008. 28(5), 592–605.
- Fraschini, F. Demartini, G. Esposti, D. *Pharmacology of Silymarin*. Clin Drug Invest. 2002.
- Friedman SL. *Liver fibrosis- from bench to bedside*. J Hepatol .2003; 38 ; 538 – 53.
- Friedman SL., *Cellular and molecular pathobiology of liver fibrosis and its pharmacological intervention*. Hepatology 2007; ; 590-599.
- Fujiyoshi, M. Ozaki M. *Molecular mechanism of liver regeneration and protection for treatment of liver dysfunction and diseases*. J Hepatobiliary Pancreat Sci. 2011 Jan : 18 (1) : 13-22.
- Gartner LM. *Breastfeeding and jaundice*. J Perinatol 2001; 21:S25 – S29.

- Govind, P., Article, R. and Sahni, Y.P. *A review of hepatoprotective activity of silymarin*. IJRAP .2011. 2: 75–79.
- Gressner AM., et al. *Modern pathogenik concepts of liver fibrosis suggest stellate cells and TGF- β as mayor player and therapeutic targets*. J. cell. Mol. Med. 2006; 10; 76–99.
- Grunhage F., Iammert F. 2003. *Assesment of hepatic fibrosis in chronic viral hepatitis*. Hepatology- A clinical textbook. 291 – 300.
- Guha I N. Iredale J P. 2007. *Textbook of Hepatology From Basic Science to Clinical Practice, Third Edition*. Blackwell Publishing . 604 – 19.
- Gum, E.T., Swanson, R.A., Alano, C., Liu, J., Hong, S., Weinstein, P.R., et al. 2004. *Human Serum Albumin And Its N-Terminal Tetrapeptide (DAHK) Block Oxidant-Induced Neuronal Death*. Stroke. 35: 590-595.
- Guyton, A.C., dan Hall, J.E. 2008. *Buku Ajar Fisiologi Kedokteran*. Edisi 11. Jakarta: EGC
- Harmita dan Radji, M. 2008. *Buku Ajar Analisa Hayati Edisi 3*. Jakarta: EGC.
- Halliwell dan Gutteridge.1999. *Free Radical in Biology and Medicine*. New York. Oxford University Press Inc., New York.
- Hayani, E. M. 2006. *Analisis kandungan kimia rimpang temulawak*, Pusat Penelitian dan Pengembangan Peternakan. Bogor : 309–312.
- Jaswal, A., Sinha, N., Bhadauria, M., Shrivastava, S. and Shukla, S. *Therapeutic potential of thymoquinone against anti-tuberculosis drugs induced liver damage*. Environmental Toxicology and Pharmacology. 2013 .36: 779–786.
- Jatwa, R., Kar, A. and Pradesh, M. *Protective effect of L-ornithine-L-aspartate and silymarin on chemically induced kidney toxicity and thyroid dysfunction in mice*. EXCLI Journal 7. 2008: 139–150.
- Junqueira, LC., 2007. *Persiapan jaringan untuk pemeriksaan mikroskopik. Histology Dasar: teks dan atlas*. Edisi 10. Jakarta : EGC.
- Kaplan M, dkk. *Hemolysis and hyperbilirubinemia in ABO blood group heterospecific neonates*. J Pediatr. 2010 November ; 157(5): 772–777.
- Kumar, Cotran, dan Robin. 2007. *Buku Ajar Patologi*. Edisi 7. Penerbit Buku Kedokteran EGC. Jakarta.
- Khafaji, A., dan Web, A.R. *Should Albumin Be Used To Correct Hypoalbuminemia In The Critically Ill*. TATM. 2003. 5: 392-396.
- Kumar V., Cotran R.S., Robbins S.L. 2007. *Buku Ajar Patologi*. Edisi 7. Jakarta: EGC. Hal 186-94, 200-11.
- Mailankot, M., Jayalekshmi, H., Chakrabarti, A., & Vasudevan, D. M. *Effect of exogenous L-ornithine L-aspartate on ethanol induced testicular injury in Wistar rats*. Indian Journal of Clinical Biochemistry, 2009. 24(1), 94–97.

- Malloy HT, Evelyn KA. *The determination of bilirubin with the photoelectric colorimeter*. J Biol Chem 1937; 119 : 481-490.
- Mary L.A. , Charles B. 2008. *Clinical Laboratory Parameters for CrI : CD (SD) Rats*. Charles River Laboratories. Wilmington.
- Mariah, N.I. dan Sutrisno E., 2013. *Efektifitas Ekstrak Biji Jintan Hitam (Nigella sativa) Terhadap Bakteri Streptococcus Pyogenesis, K. Pneumonia, P. Aeruginosa, dan Proteus Vulgaris sebagai antibakteri*. Skripsi. Medan : Fakultas Farmasi Universitas Sumatra Utara.
- McIntyre, Neil. 2007. *Textbook of Hepatology From Basic Science to Clinical Practice 3rd edition*. Blackwell Scientific Publishing, London.
- Meilisa. 2009. *Uji Aktivitas Anti Bakteri dan Formulasi dari Sediaan Kapsul dalam Ekstrak Etanol Rimpang tumbuhan Temulawak (Curcuma xanthorrhiza, Roxb) terhadap Beberapa Bakteri*. Skripsi. Medan : Fakultas Farmasi Universitas Sumatra Utara.
- Mittermayr M, Streif W, Haas T et al: *Hemostatic changes after crystalloid or colloid administration during major orthopedic surgery: the role of fibrinogen administration*, Anesth Analg 105:905, 2007.
- Muslimah, Amalia Ghassani. 2016. *Efek Kombinasi Cucurma xanthorrhiza dan Nigella sativa Terhadap Histopatologi Hepar Pada tikus yang Diinduksi CCl₄*. Skripsi. Malang : Fakultas Kedokteran Universitas Brawijaya.
- Netter, Frank H. 2014. *Atlas of Human Anatomy 25th Edition*. Jakarta: EGC.
- Nicholson, J.P., dan Wolmaran, M.R. *The Role Of Albumin In Critical Illness*. Br. J. Anasth. 2000. 85: 599-610.
- Orbell, J. and Coulepis, T. 2007. *Medicinal Plants* . 11: 726–743.
- Panjaitan RGP, Handharyani E, Chairul, Masriani, Zakiah Z, Manalu W. 2007. *Pengaruh pemberian karbon tetraklorida terhadap fungsi hati dan ginjal tikus*. Makara Kesehatan 11 (1): 11-16.
- Permata, Kautsarita Mayang. 2009. *Pengaruh pemberian ekstrak jintan hitam (nigella sativa) Terhadap perubahan histopatologik hepar mencit balb/c Yang diinfeksi Salmonella typhimurium*. Skripsi. Semarang: Fakultas Kedokteran Universitas Diponegoro.
- Poo, J. L., Góngora, J., Sánchez-Avila, F., Aguilar-Castillo, S., García-Ramos, G., Fernández-Zertuche, M. Uribe, M. *Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy*. Results of a randomized, lactulose-controlled study. Annals of Hepatology, 2006. 5(4), 281–8.
- Rahardjo, Mono dan Rostiana, Oti. 2005. *Budidaya tanaman temulawak*. Sirkuler. No. 11 : 13-15.

- Salmi HA, Sarna S. *Effect of silymarin on chemical, functional, and morphological alterations of the liver*. Scand J Gastroenterol 2001; 17: 517-21.
- Sastroasmoro, P, Sarwono. 2002. *Dasar – Dasar Metodologi Penelitian Penelitian Klinis, edisi 2 (ed-2)*. Jakarta : CV. Sagung Seto
- Schuppan D et al, *Liver cirrhosis*, Lancet 2008; 371; 838 – 51.
- Shaker, M.E., Zalata, K.R., Mehal, W.Z., Shiha, G.E. and Ibrahim, T.M. *Comparison of imatinib , nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress , injury and fibrosis*. Toxicology and Applied Pharmacology. 2011. 252: 165–175.
- Sharma RA. *Phase I Clinical Trial of oral curcumin biomarkers of systemic activity and compliance*. Clinical Cancer Res. 2004; 10: 6847-54.
- Simanjuntak, Kristina. *Radikal Bebas dari Senyawa Toksik Karbon Tetraklorida (CCl₄)*. Bina Widya Vol. 18 No. 01, April 2007. Fakultas Kedokteran UPN “Veteran”. Jakarta.
- Silbernagl S.,Lang F.,*Fibrosis dan sir-osis hati. Teks dan Atlas berwarna; Patofisiologi*.EGC. 2003; 172 -73.
- Silbernagl, S., & Florian, L. 2009. *Respiration, acid-base balance. Color atlas of patophysiology* (Vol. 93). <http://doi.org/10.1136/bjo.2010.193169>.
- Sitorus, M, 2010, *Kimia Organik Umum*, Graha Ilmu, Yogyakarta.
- Sjarif DM, Lestari ED, Mexitalia M, Nasar SS. *Buku ajar nutrisi pediatrik dan penyakit metabolik. Jilid 1*. Badan penerbit Ikatan Dokter Anak Indonesia.2011.
- Sloane, E., 2004. *Anatomi dan Fisiologi Untuk Pemula*. Penerbit Buku Kedokteran (EGC). Jakarta
- Snell, R. S., 2006. *Anatomi Klinik*. Edisi 6. Jakarta:EGC. 350-360
- Stahl, E., 1985, *Analisis Obat Secara Kromatografi dan Mikroskopi*. Diterjemahkan oleh Kosasih Patmawinata dan Sudiro S. ITB, Bandung.
- Putz R, Pabst R. 2007. *Atlas anatomi manusia sobotta jilid 2*, edisi ke–22. Jakarta: EGC.
- Uhing, M.R. The Albumin Contro Versy. *Clin Perinatol*. 2004. 31(3): 475- 488. <http://www.ncbi.nlm.nih.gov/pubmed/15325533>. diakses pada tanggal 1 Januari 2016.
- Vincent, J.L. *Hypoalbuminemia In Acute Illness*. Annals Of Surgery. 2003. 237: 319-340.
- Wahlefeld AW, Herz G, Bernt E. *Modification of the Malloy-Evelyn Method for a Simple, Reliable Determination of Total Bilirubin in Serum*.Scan J Clin Lab Inves 1972; 29 Supplement 126: Abstract 11.12.
- Wang, Y., Liang, W., Pan, W., Law, W., Hu, J., Ip, D.T., Wayne, M.M., Ng, T. and Wan, D.C. *Phytomedicine Silibinin , a novel chemokine receptor type 4 antagonist , inhibits chemokine ligand 12-induced migration in breast cancer cells*. European Journal of Integrative Medicine.2014. 21: 1310–1317.

WHO, 2003, *Traditional medicine*, <http://www.who.int/mediacentre/factsheets/fs134/en/>, diakses 1 Januari 2016.

WHO. 2004. *Environmental Health Criteria 208*. Corrigenda Published, Netherlands.

Wong RJ, Stevenson DK, Ahlfors CE, Vreman HJ. *Neonatal jaundice: Bilirubin physiology and clinical chemistry*. *Neoreviews* 2007 ; 8 : 58-67.

Woreta, T. a., & Alqahtani, S. a *Evaluation of abnormal liver tests*. *Medical Clinics of North America*, 2014 .98(1), 1–16.

UNIVERSITAS BRAWIJAYA

